SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 28, 2022 - INSD

New York, New York--(Newsfile Corp. - January 20, 2022) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. ("Instadose") (OTC Pink: INSD) between December 8, 2020 and November 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Virginia. To get more information go to:

https://www.zlk.com/pslra-1/instadose-pharma-corp-f-k-a-mikrocoze-inc-loss-submission-form?prid=22327&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/111087_479306_logo.jpg

Instadose Pharma Corp. f/k/a Mikrocoze, Inc. NEWS - INSD NEWS

CASE DETAILS: According to the filed complaint: (i) Instadose had performed inadequate due diligence into the business combination with Instadose Canada and/or ignored significant red flags associated with Instadose Canada; (ii) Instadose's internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (iii) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Instadose, you have until February 28, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Instadose securities between December 8, 2020 and November 24, 2021., you may be entitled to compensation without payment of any out-of-pocket costs or fees.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/instadose-pharma-corp-f-k-a-mikrocoze-inc-loss-submission-form?prid=22327&wire=5 or call 212-363-7500 to discuss the case with Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by corporations.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky, have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 80 employees, is committed to fostering, cultivating and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111087

info